Immediate Impact
1 from Science/Nature 58 standout
Citing Papers
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Drug resistance in ovarian cancer: from mechanism to clinical trial
2024 Standout
Works of B.J. Monk being referenced
Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients
2020
Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer.
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| B.J. Monk | 179 | 126 | 73 | 120 | 50 | 339 | |
| Michaela Bártů | 115 | 99 | 75 | 110 | 50 | 355 | |
| Lucía González‐Cortijo | 173 | 184 | 75 | 103 | 26 | 403 | |
| N. Sakuragi | 211 | 180 | 36 | 80 | 28 | 411 | |
| Tomoko Kurita | 100 | 135 | 34 | 91 | 49 | 347 | |
| Yusuke Matsuura | 199 | 201 | 62 | 55 | 42 | 393 | |
| M.M. Boisen | 162 | 188 | 44 | 64 | 45 | 381 | |
| Diana Lim | 228 | 209 | 95 | 51 | 29 | 403 | |
| Giuseppa Maltese | 211 | 198 | 85 | 114 | 24 | 386 | |
| Anna Dańska-Bidzińska | 184 | 167 | 38 | 79 | 40 | 388 | |
| Jean Paul Guastalla | 125 | 65 | 52 | 183 | 30 | 394 |
All Works
Loading papers...